Big pharma — Maximum earnings, minimum responsibilities

Richa Chintan

People’s Dispatch | August 24, 2021

Photo: Wikimedia Commons

The contrast between the devastating effects of the COVID-19 pandemic on the lives and livelihood of the working-class population and the soaring profits of big pharma companies in the corresponding period is abhorrent.

Despite the huge jump in revenues during the global crisis and a forecast for the continuation of the good run—owing to an assured market for vaccines, drugs and diagnostics in the years to come—big pharma is reportedly lobbying against the proposed global deal on tax overhaul. Last month, about 130 countries agreed to the US call for a global minimum rate of corporate tax of 15%.

Read More »

Cutting edge pharmaceutical production and scientific research in Cuba

Granma | 14 February, 2017

Director Carlos Manuel García noted that the National Clinical Trials Coordinating Center has expert staff in all provinces. Photo: Anabel Díaz

Browsing the web reveals an extraordinary number of sites citing the strength of Cuba’s pharmaceutical and biotechnology industries, along with the number of countries purchasing Cuban products for their populations. Yet the corporate media makes little mention of this accomplishment.

Among the country’s most important, latest-generation medications is Heberprot P, used by more than 225,000 patients in many countries to treat diabetic foot ulcers and avoid a large percentage of amputations. It is currently administered via nano-capsules, making the drug’s anti-microbial impact very effective.

Read More »